Since now, the PI3K/AKT [41, 42], RAS-RAF-MAPK [43, 44], and STAT3 [45] signaling pathway were identified as a regulatory axis in the resistance to trastuzumab in HER2-positive cancers. The gene discussed is ERBB2; the disease is cancer.